Introduction: This study aims to explore the genetic contributing to obesity and the single nucleotide polymorphisms(SNPs) involved in its development. Additionally, the relationship between side effects and phenotypes of polymorphisms in the human genome has been examined.
Methods: Data were collected through NCBI database and the analysis was performed using pharmacogenetics software MegaGene for analyzing polymorphic information and identifying drug related side effects with a genetic basis.
Results: The results revealed that three common polymorphisms in the FTO gene, RS9939609, RS8050136, RS1421085, and MC4R gene, polymorphisms Rs17782313, RS2229616, as well as the RS1799883 polymorphism in the FABP2 gene, are involved in the indication of the disease. One of the most important achievements of the research is detection the role of drug side effects based on the genetics of each individual. It has identified the genetic probability of side effects and the genes and polymorphisms involved in the genetics indication of these side effects.
Conclusion: These findings suggest that before prescribing medication and starting therapy for the treatment of hypertension, it is essential to conduct genetic testes to check for presence of polymorphisms in common gene such as FTO, BRCA2, and MLH1 in patients. If polymorphisms are detected, medications with fewer side effects should be prescribed to the patient. This approach ensures that patients receive medication with fewer side effects based on their genetic.
Keywords: Obesity, Single Nucleotide Polymorphism ,MegaGene, Hypertension, FTO